{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T18:18:03Z","timestamp":1671301083597},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Translational Medicine"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.retram.2016.08.002","type":"journal-article","created":{"date-parts":[[2016,11,3]],"date-time":"2016-11-03T23:01:59Z","timestamp":1478214119000},"page":"15-19","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["CALR gene mutational profile in myeloproliferative neoplasms with non-mutated JAK2 in Moroccan patients: A case series and germline in-frame deletion"],"prefix":"10.1016","volume":"65","author":[{"given":"W.","family":"Smaili","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Doubaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.Z.","family":"Laarabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Lyahyai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kerbout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mikdame","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Sefiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.retram.2016.08.002_bib0160","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Editorial: some speculations on the myeloproliferative syndromes","volume":"6","author":"Dameshek W:","year":"1951","journal-title":"Blood"},{"key":"10.1016\/j.retram.2016.08.002_bib0165","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.retram.2016.08.002_bib0170","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.retram.2016.08.002_bib0175","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.retram.2016.08.002_bib0180","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.retram.2016.08.002_bib0185","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182\u00a0patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.retram.2016.08.002_bib0190","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.retram.2016.08.002_bib0195","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with non-mutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.retram.2016.08.002_bib0200","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/BF01878089","article-title":"Zwei Falle von Leukamie mit eigenthumlichem Blut- resp. Knochenmarksbefund (two cases of leukemia with peculiar blood and bone marrow findings, respectively)","volume":"78","author":"Heuck","year":"1879","journal-title":"Arch Pathol Anat Physiol Virchows"},{"key":"10.1016\/j.retram.2016.08.002_bib0205","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.leukres.2006.12.002","volume":"31","author":"Mesa","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.retram.2016.08.002_bib0210","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/BF01891529","article-title":"Hammorhagische thrombocythamie bei vascularer schrumpfmilz","volume":"292","author":"Epstein","year":"1934","journal-title":"Virch Arch (Pathol Anat)"},{"key":"10.1016\/j.retram.2016.08.002_bib0215","first-page":"1497","article-title":"A minute chromosome in human chronic granulocytic leukemia","volume":"132","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"10.1016\/j.retram.2016.08.002_bib0220","series-title":"Who classification of tumors of haematopoietic and lymphoid tissues","author":"Swerdllow","year":"2008"},{"issue":"8","key":"10.1016\/j.retram.2016.08.002_bib0225","doi-asserted-by":"crossref","first-page":"E121","DOI":"10.1002\/ajh.23743","article-title":"Type\u00a01 versus Type\u00a02 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027\u00a0patients","volume":"89","author":"Tefferi","year":"2014","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.retram.2016.08.002_bib0230","doi-asserted-by":"crossref","first-page":"e0035","DOI":"10.5041\/RMMJ.10169","article-title":"Calreticulin mutations in myeloproliferative neoplasms","volume":"5","author":"Lavi","year":"2014","journal-title":"Rambam Maimonides Med J"},{"key":"10.1016\/j.retram.2016.08.002_bib0235","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13045-014-0048-6","article-title":"The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"7","author":"Wu","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"15","key":"10.1016\/j.retram.2016.08.002_bib0240","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1182\/blood-2014-01-550434","article-title":"CALR exon\u00a09 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.retram.2016.08.002_bib0245","first-page":"1","article-title":"Calreticulin: a multifaceted protein","volume":"4","author":"Mendlovic","year":"2010","journal-title":"Nat Educ"},{"issue":"15","key":"10.1016\/j.retram.2016.08.002_bib0250","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood-2014-07-588426","article-title":"The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"issue":"21.","key":"10.1016\/j.retram.2016.08.002_bib0255","article-title":"In-frame exon 9 CALR deletions co-occur with other alterations in the JAK-STAT pathway in myeloproliferative neoplasms","volume":"124","author":"Yongbao","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.retram.2016.08.002_bib0260","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.retram.2016.08.002_bib0265","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation between molecularly-annotated essential thrombocythemia, polycythemia vera and primary myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.retram.2016.08.002_bib0270","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia","volume":"123","author":"Rotunno","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.retram.2016.08.002_bib0275","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2014.148","article-title":"Calreticulin mutations and long-term survival in essential thrombocythemia","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.retram.2016.08.002_bib0280","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/asheducation-2011.1.215","article-title":"Management of essential thrombocythemia","volume":"2011","author":"Cervantes","year":"2011","journal-title":"Hematol Am Soc Hematol Educ Prog"},{"issue":"8","key":"10.1016\/j.retram.2016.08.002_bib0285","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.retram.2016.08.002_bib0290","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1056\/NEJMc1401255","article-title":"Interferon alfa therapy in CALR-mutated essential thrombocythemia","volume":"371","author":"Cassinat","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.retram.2016.08.002_bib0295","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/asheducation-2009.1.636","article-title":"Therapeutic potential of JAK2 inhibitors","author":"Verstovsek","year":"2009","journal-title":"Hematol Am Soc Hematol Educ Prog"},{"issue":"3","key":"10.1016\/j.retram.2016.08.002_bib0300","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s40265-015-0351-8","article-title":"Ruxolitinib: a review of its use in patients with myelofibrosis","volume":"75","author":"Plosker","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.retram.2016.08.002_bib0305","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.64","article-title":"Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis","volume":"5","author":"Barbui","year":"2015","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.retram.2016.08.002_bib0310","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000358580","article-title":"Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond","volume":"133","author":"Michiels","year":"2015","journal-title":"Acta Haematol"}],"container-title":["Current Research in Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318616300319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318616300319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T03:43:22Z","timestamp":1601178202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452318616300319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S2452318616300319"],"URL":"https:\/\/doi.org\/10.1016\/j.retram.2016.08.002","relation":{},"ISSN":["2452-3186"],"issn-type":[{"value":"2452-3186","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CALR gene mutational profile in myeloproliferative neoplasms with non-mutated JAK2 in Moroccan patients: A case series and germline in-frame deletion","name":"articletitle","label":"Article Title"},{"value":"Current Research in Translational Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.retram.2016.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}